Minimal residual disease assessment in multiple myeloma by multiparametric flow cytometry

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F17%3AE0106559" target="_blank" >RIV/00843989:_____/17:E0106559 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/17:00097851 RIV/65269705:_____/17:00067228

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Minimal residual disease assessment in multiple myeloma by multiparametric flow cytometry

Original language description

Background: Progress in treatment of multiple myeloma extensively increased patient remission rates, so minimal residual disease (MRD) detection becomes essential to assess the effectivity of treatment and depth of complete response. Nowadays, multiparametric flow cytometry (MFC) is the most used method for monitoring of MRD presence in the bone marrow of multiple myeloma patients; however, detection on molecular level can be used as well. It is evident that choice of protocol used for MFC-MRD assessment can significantly affect required results; nevertheless, standardized and highly sensitive approach of “next generation flow” is already available. Although benefit of MRD assessment as an independent predictor of progression-free survival and overall survival is known, very recent research showed that MRD-negative status surpasses the prognostic value of complete response achievement for progression-free survival and overall survival. Aim: This review is focused on use MFC in MRD assessment in multiple myeloma. The technical aspects and clinical benefits of this approach are mentioned as well. Conclusion: The information about MRD level detected by highly sensitive and reproducible MFC can be potentially used as a biomarker to evaluate the efficacy of different treatment strategies, help on treatment decisions and act as a surrogate for overall survival in multiple myeloma patients.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NV17-30089A" target="_blank" >NV17-30089A: In-depth genomic analysis of residual clone in multiple myeloma: approach for individualized targeted therapy</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Klinická onkologie

ISSN

0862-495X

e-ISSN

1802-5307

Volume of the periodical

30

Issue of the periodical within the volume

suppl.2

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

1

Pages from-to

2s21-2s28

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85029518178